阿尔法同核素转化后的修饰:帕金森病治疗的潜在标?
Viviana Brembati1, Gaia Faustini1, Francesca Longhena1
1Division of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Frontiers in molecular neuroscience
|June 12, 2023
概括
阿尔法-同核素 (α-Syn) 的翻译后修饰 (PTM) 在帕金森病 (PD) 和其他同核素病变中至关重要. 调节这些PTM为这些神经退行性疾病提供了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 帕金森病 (PD) 是一种常见的神经退行性疾病,其特征是运动症状.
- 关键的神经病理特征包括多巴胺基神经元损失和由α-synuclein (α-Syn) 纤维组成的Lewy体 (LB).
- α-Syn聚合是PD和其他同核蛋白病变的核心,如LB (LBD) 和多个系统缩 (MSA) 的痴呆症.
研究的目的:
- 审查α-Syn后翻译修饰 (PTMs) 在PD病理生理学中的关键作用.
- 突出α-Syn PTMs作为同核蛋白病变的生物标志物的潜力.
- 强调α-Syn PTM作为神经退行性疾病的创新治疗点.
主要方法:
- 文献综述,重点关注同核蛋白病变中的α-Syn PTM.
- 分析各种PTM (酸化,化,乙化等) 的影响. 在α-Syn聚合和功能上.
- 讨论针对α-Syn PTMs的治疗策略.
主要成果:
- α-Syn PTMs显著影响其聚合,溶解性,周转率和膜结合.
- PTMs可以改变α-Syn的结构状态,影响其播种能力和聚合倾向.
- 特定的PTM与PD和相关的同核蛋白病变的进展有关.
结论:
- α-Syn PTM 在同核蛋白病变的病理生理学中起着关键作用.
- 向α-Syn PTMs为开发新型诊断和治疗方法提供了一个有希望的途径.
- 需要进一步的研究来克服开发PTM调节疗法的挑战.
关键词:
帕金森病是帕金森氏症的一种疾病.阿尔法合成核素是什么?生物标志物 生物标志物后翻译修改 后翻译修改合成核蛋白病变 (synucleinopathies) 是一种同核蛋白病变.治疗目标是治疗的目标.更多相关视频
09:36Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
Published on: August 13, 2017
6.8K
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
6.0K
相关概念视频
Parkinson's Disease: Overview
611
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
611
Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
